On June 18, the FDA approved lenacapavir, a revolutionary injectable medication for high-risk individuals to prevent HIV, required only twice per year. This approval signifies a major advancement in HIV prevention, improving adherence over daily pill regimens. Clinical trials demonstrated lenacapavir's high efficacy, achieving 96% protection for cisgender women and 100% for men who have sex with men and gender-diverse populations. While this breakthrough offers significant hope in the fight against HIV, concerns remain about achieving its full potential due to budget cuts in vital U.S. programs for HIV treatment and prevention globally.
The approval of lenacapavir, requiring a twice-yearly injection, represents a significant leap in HIV prevention efforts, especially improving compliance over daily pill regimens.
Dr. David Ho emphasized that the single-use injection is a breakthrough and its potential to curtail the HIV epidemic could be transformative for high-risk individuals.
Collection
[
|
...
]